Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Hansen Medical: Firm reported a 43% drop in second-quarter revenues Aug. 4 -- to $3.3 million from $5.8 million in the same quarter of 2008 -- with lower-than-expected sales of the Sensei robotic catheter system. Hansen shipped six Sensei systems in the quarter, but only recognized revenue on three. Firm anticipates FDA clearance of an enhanced Sensei platform and Artisan catheter in the third quarter, and hopes to launch a smaller, more flexible ablation catheter in Europe in early 2010. The firm is working on a new platform for complex vascular procedures, but CEO Fred Moll says a clinical trial is not likely to begin before 2010 (1"The Gray Sheet" Dec. 8, 2008)

You may also be interested in...

Volcano Defies Downward Trend In Imaging Market With 24% Q1 Sales Growth

Despite a scarcity of capital available to hospitals to buy imaging equipment, Volcano placed 74% more intravascular ultrasound (IVUS) consoles in the first quarter of 2009 than it did in the same quarter a year ago, the company reported May 7

Hologic Expects 2010 Launch Of Tomosynthesis System After FDA Panel Delay

Hologic is now forecasting a late 2010 launch of its Selenia Dimensions tomosynthesis three-dimensional mammography system, after recent discussions with FDA led the firm to back out of a planned June advisory panel review

Piper Jaffray Healthcare Conference In Brief

Qiagen: Firm will pursue full pre-market approval for Ensemble, "the first ever continuous loading molecular diagnostic instrument," Qiagen Senior VP of R&D Jim Godsey announced Dec. 2 at the Piper Jaffray Healthcare Conference in New York City. Ensemble is compatible with Hybrid Capture human papilloma virus screening technology. According to Qiagen, the Ensemble JC2000 instrument can run 2,000 specimens per one eight-hour cycle and 5,000 specimens in two back-to-back shifts. The company also is developing a model for low-to-medium throughputs. Clinical trials, which likely will include 30,000-40,000 specimens, will begin in the first half of 2009, Godsey says. Qiagen gained Hybrid Capture 2, the only FDA-approved molecular HPV screening test, when it acquired Digene in 2007. Qiagen dominates the U.S. HPV market now, but will soon face competition from Hologic/Third Wave's Cervista, which is pending PMA approval, and down the line, from Gen-Probe (Aptima) and diversified drug giant Roche (Amplicor)





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts